E7208: A randomized phase II trial of irinotecan and cetuximab (IC) versus IC plus ramucirumab (ICR) in second-line therapy of KRAS wild-type colorectal cancer (CRC).
Howard S. Hochster
No relevant relationships to disclose
Paul J. Catalano
No relevant relationships to disclose
Edith P. Mitchell
No relevant relationships to disclose
Deirdre Jill Cohen
No relevant relationships to disclose
Peter J. O'Dwyer
Other Remuneration - Lilly
Al Bowen Benson
Consultant or Advisory Role - Lilly/ImClone